Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences. Concentra’s parent company Tang Capital Partners has a track record of swooping in to try to acquire struggling biotechs. The company, along with Tang Capital Management and its CEO Kevin Tang, already own 9.9% of Kezar.
Read the full article: Kezar Rejects Concentra Bid That ‘Substantially Undervalues’ the Biotech //
Source: https://www.fiercebiotech.com/biotech/kezar-rejects-concentra-buyout-substantially-undervalues-biotech